When the Food and Drug Administration held a public meeting on positron emission tomography drugs in early March, its organizers were pleasantly surprised by the number of participants.
When the Food and Drug Administration held a public meeting on positron emission tomography drugs in early March, its organizers were pleasantly surprised by the number of participants.
